Certerra has developed a unique whole-brain assay to screen drugs for neuropsychiatric and neurological disorders.
Whole-brain Pharmacomapping equals better CNS drug discovery.
We aim to radically improve predictability from preclinical
studies to clinical trials.
Certerra's drug-screening method, called "pharmacomapping", combines cutting-edge brain imaging and sophisticated statistical analyses to quantify drug-evoked brain activation at cellular resolution in animal models.
For any given drug, Certerra's process generates a
map of whole-brain drug-evoked activation (or
inhibition) in the animal model i.e., a whole-brain
Certerra offers pharmacomapping as a CRO to a broad spectrum of pharmaceutical companies developing treatments for neurodevelopmental, psychiatric, and neurodegenerative disorders.
Our central hypothesis is that the effects a drug has are largely determined by which neurons it activates. Thus,
we assert that CNS clinical trial unpredictability is in large part due to the lack of methods for mapping these
relationships. We have bridged this gap by developing an automated Pharmacomap platform that allows us to
visualize and then quantify drug-evoked brain activation at single-neuron resolution.
Our Services Include:
Pharmacomapping Level I
Drug-evoked brainwide c-fos mapping in naive mice,
acute or chronic protocols.
Pharmacomapping Level II
Computational comparisons to a proprietary Clinical
Pharmacomap Library of FDA-approved drugs.
Pharmacomapping Level III
Brainwide c-fos mapping in conjunction with disease-relevant
Alzheimer’s mouse models
Brainwide mapping of beta amyloid or other AD
Pharmacomapping in Alzheimer’s mouse models
Brainwide c-fos mapping in conjunction with beta
Possibility to develop custom assays with a broad
range of IHC-compatible antibodies.
Get in Touch
Broad Hollow Bioscience Park
3 Bioscience Park Drive
Farmingdale, NY 11735
+1 631 227 5040